Adam’s Take
Insights and opinions from senior biotech writer Adam Feuerstein
Most Read
STAT Plus: For Cytokinetics, an FDA rejection of its heart drug would help, not hinder
STAT Plus: An Anavex study spin job sullies an otherwise spectacular Alzheimer’s conference
STAT Plus: Northwest Bio study of brain cancer vaccine still falls short
STAT Plus: New results show Cassava’s Alzheimer’s drug has placebo-like efficacy
STAT Plus: Reata’s ‘toss up’ drug approval decision is in the unpredictable hands of FDA’s Billy Dunn
STAT Plus: Biotech is full of chest-thumping press releases. This one thumps really hard
STAT Plus: Mark Schoenebaum was the best biotech analyst ever. Better still, he was a great person
All Coverage
advertisement
